Plasmodium co-infection protects against chikungunya virus-induced pathologies

Teck-Hui Teo¹, Fok-Moon Lum¹, Khairunnisa Ghaffar¹, Yi-Hao Chan¹², Siti Naqiah Amrun¹, Jeslin J.L. Tan¹, Cheryl Y.P. Lee¹², Tze-Kwang Chua¹, Guillaume Carissimo¹, Wendy W.L. Lee¹, Carla Claser¹, Ravisankar Rajarethinam³, Laurent Rénia¹ & Lisa F.P. Ng¹²⁴

Co-infection with Plasmodium and chikungunya virus (CHIKV) has been reported in humans, but the impact of co-infection on pathogenesis remains unclear. Here, we show that prior exposure to Plasmodium suppresses CHIKV-associated pathologies in mice. Mechanistically, Plasmodium infection induces IFNγ, which reduces viraemia of a subsequent CHIKV infection and suppresses tissue viral load and joint inflammation. Conversely, concomitant infection with both pathogens limits the peak of joint inflammation with no effect on CHIKV viraemia. Reduced peak joint inflammation is regulated by elevated apoptosis of CD4⁺ T-cells in the lymph nodes and disrupted CXCR3-mediated CD4⁺ T-cell migration that abolishes their infiltration into the joints. Virus clearance from tissues is delayed in both infection scenarios, and is associated with a disruption of B cell affinity-maturation in the spleen that reduces CHIKV-neutralizing antibody production.
Arthralgic alphaviruses are mosquito-borne pathogens that induce musculoskeletal disease accompanied by fever, rash and joint pain in infected patients. Over the past two decades, the spread of arthralgic alphaviral diseases has accelerated and raised public-health concern due to epidemics of Chikungunya (CHIKV), O’nyong’nyong, Sindbis, Ross River, Barmah Forest and Mayaro viruses in humans. Outbreaks of these alphaviruses are usually restricted to specific continents. However, since the initial outbreaks on islands of the Indian Ocean in 2004, CHIKV has rapidly spread into India, Southeast Asia and tropical America and ongoing local transmission is now established in many of these affected countries.

The expansion of CHIKV into areas with endemic malarial Plasmodium parasites in circulation increases the likelihood of co-infection between CHIKV and Plasmodium. High-risk areas of co-infection include Africa, India, Southeast Asia and Latin America, and have confirmed the presence of both CHIKV and Plasmodium in affected patients from seroprevalence studies. Although most co-infection reports are derived from African cohorts, the global frequency of CHIKV and Plasmodium co-infection is likely under-estimated as arbovirus screening is not systematic but performed only when patients are negative for malaria infection. In addition, while Aedes mosquitoes are the principal vector for CHIKV, typical malaria vectors such as Anopheles funestus and A. coustani, collected in the field were recently shown to be infected with CHIKV. This increases the likelihood of concurrent co-infection of Plasmodium and CHIKV via competent vectors infected with both pathogens.

The impact of Plasmodium and arbovirus co-infection on host susceptibility and pathological severity is largely unknown. Our previous work reported the impact of CHIKV co-infection on malaria pathogenesis in vivo using a mouse model infected with P. berghei-ANKA (PbA). We found that concurrent co-infection with PbA led to protection against parasite-induced neuropathology, specifically preventing experimental cerebral malaria (ECM)-induced mortality by disrupting the CXCR3 chemokine–chemokine receptor network.

In this present study, we explored the effects of Plasmodium co-infection on the severity of CHIKV infection and virus-induced arthralgia. We found that co-infection suppresses CD4+ T-cell responses to protect against severe CHIKV-induced joint pathology, while disrupted B-cell affinity maturation in the spleen delays viral resolution in the joints. This is the first study to describe Plasmodium-induced host immune regulation that directly alters virus clearance and CHIKV-induced joint pathology during co-infection. These findings could be applied to improve management of chikungunya disease in regions with Plasmodium co-endemicity.

Results

Co-infection prevents severe CHIKV joint inflammation. In this study, we used the well-defined CHIKV joint-footpad mouse model where CHIKV infection alone induces measurable joint swelling that peaks at ~6 days post infection (dpi) and lasts ~14 dpi, with a viraemic profile of 10–12 dpi. We also used two different species of rodent Plasmodium, PbA which causes fatal ECM, and Py17x which induces uncomplicated, non-lethal malaria. To understand the impact of Plasmodium infection on CHIKV-induced pathology, four different CHIKV co-infection scenarios were designed to reflect situations where co-infection of CHIKV and Plasmodium occur concurrently or sequentially.

In the first scenario, mice were pre-infected with PbA or Py17x, 4 days before CHIKV infection when mice mount acute Plasmodium-induced responses at the time of co-infection (Fig. 1a, b). In the second scenario, mice were concurrently co-infected with PbA or Py17x and CHIKV (Fig. 1c, d). In the third scenario, animals were infected with PbA or Py17x 4 days after CHIKV infection when mice mount acute CHIKV-induced responses at the time of co-infection (Supplementary Fig. 1a, b). Lastly, in the fourth scenario, animals were infected with CHIKV 26 days after Py17x infection, when mice had recovered from Py17x-induced malaria (Supplementary Fig. 1c).

Mice pre-infected (~4 dpi) with lethal PbA or non-lethal Py17x have abolished CHIKV-induced joint swelling and reduced or prevented viral load in the blood throughout the entire course of disease (Fig. 1a, b and Supplementary Fig S5). Consistent with previous findings, 80% of the co-infected PbA (~4 dpi) + CHIKV mice succumbed to ECM 6–8 days after parasite infection. As such, data from the PbA (~4 dpi) + CHIKV co-infection scenario were not statistically significant from 4 dpi onwards (i.e. 8 days after parasite infection) (Fig. 1a). Concurrent CHIKV with PbA or Py17x co-infection suppressed peak joint swelling (~50%) with no effect observed for joint swelling or viraemia (Fig. 1c, d). No effects on joint swelling or viraemia were observed in mice infected with PbA or Py17x 4 days after CHIKV infection (Supplementary Fig. 1a, b) or when mice were infected with CHIKV after recovery from prior Py17x infection (Supplementary Fig. 1c).

Together, pre- and concurrent Plasmodium co-infection protects against CHIKV-induced pathology to different degrees. Importantly, the impact of co-infection on CHIKV pathology was not limited to one Plasmodium species. Thus, all subsequent studies mimicking concurrent Plasmodium and CHIKV co-infection were performed using PbA. Pre-Plasmodium (~4 dpi) and CHIKV co-infection were performed using Py17x due to the high death rate of PbA-infected mice.

Co-infection delays CHIKV resolution in the joint. CHIKV replication persists in the joints for weeks after systemic viral load is resolved. To understand the impact of co-infection on virus persistence in the joints, an infectious clone of CHIKV expressing a firefly luciferase marker that allowed tracking of virus dissemination and replication was used.

Interestingly, concurrent CHIKV + PbA co-infection had no effect on early acute CHIKV replication (1–7 dpi) and levels of joint footpad viral RNA (2 dpi), but resulted in higher levels of virus persistence in the inflamed joints from 8–22 dpi (Fig. 2a–c and Supplementary Movie 1) despite similar viraemia levels to CHIKV-infection alone (Fig. 1c). Similarly, resolution of disseminated virus in the tails and contra-lateral footpad was delayed by ~5 days in the co-infected mice (Supplementary Movie 1). Follow-up of tissue viral load beyond 22 dpi was not possible as co-infected mice succumb to PbA-induced hyperparasitaemia by 23–24 dpi.

In contrast to concurrent PbA co-infection, pre-Py17x (~4 dpi) + CHIKV co-infection suppressed early CHIKV replication in the tissue from 1–3 dpi and levels of joint footpad viral RNA on 2 dpi (Fig. 2d–f and Supplementary Movie 2). Despite this early phenotype, pre-Py17x (~4 dpi) + CHIKV co-infection led to elevated tissue viral load from 5–18 dpi in the co-infected mice compared to CHIKV-only mice (Fig. 2d, e and Supplementary Movie 2). Viral load within the joints of co-infected mice remained significantly higher until 40 dpi, and virus clearance was delayed from 40 dpi to 45 dpi (Fig. 2g).

Co-infection suppresses acute CHIKV joint pathology. Histopathological assessment was next performed on the joint tissues from CHIKV + PbA (concomitant infection) and Py17x (~4 dpi) + CHIKV infected mice at 6 dpi, when peak joint swelling was suppressed in both models (Fig. 1). Haematoxylin and eosin...
Fig. 1 Co-infection suppresses CHIKV-induced joint swelling and viral replication. **a** Joint inflammation and viraemia of CHIKV (n = 7) and PbA (−4 dpi) + CHIKV (n = 7) groups. Each blue “†” symbol represents one mouse that died of experimental cerebral malaria on the respective day. **b** Joint inflammation and viraemia of CHIKV (n = 5) and Py17x (−4 dpi) + CHIKV (n = 4) groups. For (a) and (b), Plasmodium infection was given 4 days prior to CHIKV infection, as shown in the schematic. **c** Joint inflammation and viraemia of CHIKV (n = 7) and CHIKV + PbA (n = 7) groups. **d** Joint inflammation and viraemia of CHIKV (n = 5) and CHIKV + Py17x (n = 5) groups. For (c) and (d), Plasmodium and CHIKV infection occurred concurrently, as shown in the schematic. All data were analyzed by Mann–Whitney two-tailed test (\( \ast P < 0.05 \), \( \ast\ast P < 0.01 \) and \( \ast\ast\ast P < 0.001 \)), and are representative of two independent experiments. Data represent the means ± standard deviation. Parasitaemia were not altered by co-infection and data has been published in Teo et al.\(^{19}\). Abbreviations: CHIKV, Chikungunya virus; dpi, days post infection; PbA, Plasmodium berghei-ANKA; Py17x, Plasmodium yoelii 17x
Fig. 2 Co-infection delays virus resolution in tissues and suppress acute CHIKV-induced joint pathology. Tissue viral load in a the whole body and b the joints of CHIKV (n = 5) and CHIKV + PbA (n = 6) groups. Follow-up was terminated at 22 dpi as co-infected mice died of hyper-parasitaemia between 23 and 26 dpi. Footpad viral RNA load on 2 dpi in the joints of CHIKV (n = 5) and CHIKV + PbA (n = 5) groups. Tissue viral load in d the whole body and e the joints of CHIKV (n = 7) and Py17x (−4 dpi) + CHIKV (n = 5) groups. Footpad viral RNA load on 2 dpi in the joints of CHIKV (n = 5) and Py17x (−4 dpi) + CHIKV (n = 4) groups. Footpad viral load of CHIKV (n = 6) and Py17x (−4 dpi) + CHIKV (n = 7) groups at 20 dpi, 30 dpi, 40 dpi and 45 dpi. Bioluminescence signal from the luciferase-tagged virus in both groups fell below the detection limit at 45 dpi. Representative pseudo-color images of bioluminescence signal at 20 dpi, 30 dpi, 40 dpi and 45 dpi are shown. Histopathological scoring of (h) oedema in the subcutaneous region and (i) muscle necrosis in the joints of CHIKV, CHIKV + PbA and Py17x (−4 dpi) + CHIKV (n ≥ 4 per group) at 6 dpi. j Total CD45+ cellular infiltration (flow cytometry) and infiltration of inflammatory cells in different regions of the joint (histological grading) of CHIKV, CHIKV + PbA and Py17x (−4 dpi) + CHIKV (n ≥ 4 per group) at 6 dpi. Data in a–g were analyzed by Mann-Whitney two-tailed test and h–j by one-way ANOVA with Tukey post hoc test (*P < 0.05, **P < 0.01 and ***P < 0.001). Data represent the means ± SD. Abbreviations: CHIKV, Chikungunya virus; CoIF, co-infected; dpi, days post infection; PbA, Plasmodium berghei-ANKA; Py17x, Plasmodium yoelii 17×.
clearance

B cells and CHIKV-neutralizing antibodies are essential for virus clearance. As Plasmodium co-infections aggravate tissue viral load only in the later stages of CHIKV infection (Fig. 2), IgM and IgG antibody titers were quantified. At 6 dpi of concurrent PbA and CHIKV co-infection, higher CHIKV-specific IgM titers were observed (Fig. 4a), while IgG titers (Fig. 4b) and neutralizing capacities (Fig. 4c) were similar to mice infected with CHIKV alone. However, lower CHIKV-specific total IgG titers was detected coupled with a reduction in CHIKV neutralization in co-infected mice at 15 dpi (Fig. 4b, c and Supplementary Fig. 6a). In the pre-Py17x (~4 dpi) + CHIKV co-infection scenario, mice showed lower levels of CHIKV-specific IgM and IgG and reduced CHIKV neutralization compared to mice infected with CHIKV alone at both 6 and 15 dpi (Fig. 4d–f and Supplementary Fig. 6b).

**Spleen dysregulation alters CHIKV antibodies production.** Spleen B-cell response is disrupted during Plasmodium infection due to germinal center (GC) dysregulation25–29. To determine if dysregulation in the spleen is the primary reason for the suppression of CHIKV-specific antibodies in Plasmodium and CHIKV co-infected mice (Fig. 4a–f), concurrent PbA + CHIKV co-infection was performed in splenectomised mice. Pre-Py17x co-infection was excluded due to the impact of Plasmodium induced IFNγ at the point of CHIKV infection that suppressed early acute CHIKV viral load (Fig. 3).

Interestingly, peak joint swelling at 6–7 dpi was increased by splenectomy in CHIKV-infected mice with no effect on viraemia and tissue viral load (Fig. 4g–i). Concurrent co-infection reduced peak joint swelling in splenectomised mice as in non-splenectomised controls (Fig. 4g: right panel), with no effect on viraemia (Fig. 4h). However, splenectomy restored the ability of co-infected mice to resolve tissue viral load in 8–18 dpi to comparable levels as non-splenectomised CHIKV-infected mice (Fig. 4i, j). CHIKV-specific IgM, total IgG titers and CHIKV neutralizing antibodies were also similar in both splenectomised CHIKV-infected and co-infected mice (Supplementary Fig. 7a–c). Nonetheless, splenectomy also reduced parasitaemia in co-infected mice during the later phase (10–18 dpi) of the disease (Supplementary Fig. 7d). The possible indirect impact of reduced parasitaemia on the tissue viral load in the co-infected splenectomised mice remains to be determined.

**Co-infection delays germinal center B-cell generation.** PbA infection impairs the GC response26,28 that could disrupt production of CHIKV antibodies. By adapting the flow cytometry gating strategy used in a recent study30, GC B cells were defined by B220+IgD−GL7+CD95+CD38− surface markers. Concurrent PbA and CHIKV co-infection suppressed early generation of GC B cells in the spleen at 6 dpi (Supplementary Fig. 8b; blue dots). Interestingly, a significant increase in the B220+GL7+CD95+CD38+ B-cell subset was observed in co-infected mice at 6 dpi, which was not present in CHIKV-infection only controls (Supplementary Fig. 8b). This CD38+ B-cell subset was previously suggested to be either precursors of GC-independent memory B cells or GC B-cell29. At 15 dpi, the level of GC B cells in the spleen were similar between CHIKV-infected and co-infected mice (Supplementary Fig. 8b). However, early reduction of GC B cells at 6 dpi was associated with a decline in GC-dependent CD73+ memory B cells31 at 15 dpi in co-infected mice (Supplementary Fig. 8c).

**Co-infection limits CD4+ T-cell infiltration in the joints.** To understand how co-infection alters the joint infiltrating immune subsets, immune cells were profiled by immunohistochemistry (IHC) staining and flow cytometry at 6 dpi during the peak of joint swelling. Both concurrent CHIKV + PbA and pre-Py17x (~4 dpi) + CHIKV co-infections reduced CD3+ T-cell infiltration into the subcutaneous region of the inflamed joints compared to CHIKV-infection alone (Fig. 5a, b). Flow cytometric profiling and ELISPOT assays of isolated CD4+ T cells also
showed that *Plasmodium* co-infection abrogates infiltration of activated (LFA-1+) and IFNγ-secreting CHIKV-specific CD4+ T cells into the joints (Fig. 5c–e). Finally, co-infection also suppressed infiltration of other immune subsets, including neutrophils, NK cells and CD11b+Ly6C+ monocytes/macrophages into the joints (Fig. 5f–h).

**Lymph node dysregulation alters CHIKV joint swelling.** To first determine whether co-infection could impair CD4+ T-cell expansion via the lymph nodes and disrupt infiltration into the joints, LTA–/– mice that are devoid of lymph nodes32 were assessed. Within the context of concurrent co-infection, the spleen was not of primary focus as co-infection in splenectomised
mice still reduced peak joint swelling when compared to CHIKV infected splenectomised mice (Fig. 4g). First, absence of lymph nodes delayed CHIKV-induced peak joint swelling from 6 dpi to 7–8 dpi (Fig. 6a). LTα−/− mice with concurrent CHIKV + PbA co-infection showed equivalent joint swelling as CHIKV-infected only LTα−/− animals with no effect on viraemia (Fig. 6a, b). Lack of lymph nodes also increased tissue viral load and caused extensive CHIKV dissemination from 6 dpi onwards in CHIKV-infected mice (Fig. 6c, d and Supplementary Movie 3). Concurrent co-infected LTα−/− mice still displayed an increased viral load and viral dissemination in the tissues from 10–18 dpi as compared to CHIKV-infected only LTα−/− animals (Fig. 6c, d and Supplementary Movie 3).

**Co-infection induces CD4+ T cell apoptosis in the pLN.** The popliteal lymph node (pLN) is the nearest lymph node to the site of CHIKV infection in the footpad. As immune regulation leading to suppressed joint swelling is dependent on the lymph node (Fig. 6a), expansion kinetics of CD4+ T cells in the pLN during concurrent co-infection was profiled. At 4 dpi, when pathogenic CD4+ T-cell expansion is observed, CHIKV-specific CD4+ T cells were similar between the pLN of CHIKV-infected and *Plasmodium* + CHIKV co-infected mice (Fig. 6c). These data imply similar levels of CD4+ T-cell expansion in the early stages of infection (4 dpi).

Interestingly, co-infection reduced the numbers of total and CHIKV-specific CD4+ T cells in the pLN at 5 and 6 dpi (Fig. 6e, f). *Plasmodium* is known to induce T-cell apoptosis in the secondary lymphoid organs. As early CD4+ T-cell expansion (4 dpi) was similar between single and co-infected mice, it is plausible that *Plasmodium*-induced apoptosis may reduce CD4+ T-cell numbers in the pLN of co-infected mice at 5 and 6 dpi. As expected, co-infection resulted in a higher proportion (~2–3 folds) of late apoptotic CD4+ T cells in the pLN at 5 and 6 dpi (Fig. 6g).

The reduction of CD4+ T cells from 5 dpi in the pLN on joint inflammation would depend on the timing of migration of pathogenic CD4+ T cells to the infected tissue. Therefore, CHIKV-specific CD4+ T-cell migration kinetics was assessed in the joints by flow cytometry and IFNγ ELISPOT assay. The majority of CHIKV specific CD4+ T cells infiltrated the joint between 5 and 6 dpi (Supplementary Fig. 9), thus occurring after *Plasmodium*-induced CD4+ T-cell apoptosis. Together, the reduction of peak joint swelling in co-infected mice is associated with the elevation apoptotic of pathogenic CD4+ T cells in the lymph nodes prior to their migration into the joints.

**Co-infection limits CXCR3-mediated infiltration into joints.** To assess whether reduced CD4+ T-cell numbers in the joints of co-infected mice could also be mediated by altered migration kinetics from the pLN in addition to increased levels of apoptosis, an in vivo migration assay was performed (Fig. 7a). This assay allows for the detection of any differences in cellular migration independent of the effects of increased *Plasmodium*-induced apoptosis at 5 dpi.

Concurrent *Plasmodium* and CHIKV co-infection inhibited migration of donor CD4+ T cells towards the joints of co-infected recipients by ~6-fold (Fig. 7b). Furthermore, the increase of joint swelling induced by donor's CD4+ T cells in single CHIKV-infected recipients were absence in co-infected recipients (Fig. 7c).
Immune mediators quantified from joint-footpad lysates at 6 dpi demonstrated a reduction of CCR5 ligands (MIP-1α, MIP-1β, RANTES) and CXCR3 ligand (CXCL10) in the joints (Fig. 7d). CHIKV infection in CCR5−/− mice and in WT mice with CXCR3 blockade was then performed to define the role of these two T-cell chemokine receptors. Joint swelling was suppressed at 2 dpi in CHIKV-infected CCR5−/− mice, but no effect was observed during peak swelling (mediated by CD4+ T cells) from 5-8 dpi (Supplementary Fig. 10a). No effect on viraemia was observed in CHIKV-infected CCR5−/− mice (Supplementary Fig. 10b). Conversely, CXCR3 blockade suppressed CHIKV-induced peak joint swelling from 5 to 7 dpi and reduced joint vascular leakage at 6 dpi with no effect on viraemia (Fig. 7g and Supplementary Fig. 10c, d). Importantly, CXCR3 blockade was associated with the inhibition of CD4+ T-cell infiltration into the joints (Supplementary Fig. 10e). However, CXCR3 blockade in concurrent Plasmodium and CHIKV co-infected mice did not significantly reduce joint swelling or vascular leakage at 6 dpi compared to co-infected mice with no blockade (Fig. 7e, g). CXCR3 blockade has minimal effect on viraemia (Fig. 7f). Together, these results show that CXCR3 and not CCR5, is functionally important for CD4+ T-cell migration during CHIKV infection, and co-infection sufficiently abrogates CXCR3-mediated joint swelling.

Discussion

In this study, a CHIKV mouse model that recapitulates the parameters of CHIKV infection in human patients (in terms of viral load profile and joint pathology such as tenosynovitis, myositis, oedema, and cellular infiltration) was used to understand the effects of Plasmodium co-infection on virus-induced pathology. We showed that Plasmodium infection modulates early IFNγ production, B-cell maturation and CD4+ T cell responses toward CHIKV to suppress acute joint pathology and delay tissue viral resolution in the co-infected host.

We found that elevated IFNγ production, induced by prior acute Plasmodium infection, exerts an anti-viral effect, abrogating systemic viral load and suppressing early virus replication in the joint tissue, leading to abolished joint disease. Plasmodium-induced IFNγ is produced by innate cellular subsets, including NK, NKT cells and γδ T cells. We postulate that acute Plasmodium infection triggers high IFNγ production that could “prime” cells to suppress initial viral replication in CHIKV-target cells such as fibroblasts. This effect would lead to the observed early reduction in viral load locally in the joints. Conversely, viral suppression in the monocytes/macrophages could also limit early viral dissemination to other tissues.

Disruption of germinal center architecture and germinal center B-cell maturation has been documented in experimental mouse.
and non-human primate models of Plasmodium.\textsuperscript{25–29} Disruption of B-cell homeostasis has been reported in Plasmodium-infected patients\textsuperscript{38}. Consistent with previous studies\textsuperscript{25–29}, Plasmodium co-infection delays early (6 dpi) generation of GC B cells (\textsuperscript{2B20+GL7+CD95+CD38\textsuperscript{−}}), which leads to reduced GC-dependent CD73 memory B cells at a later stage of infection (15 dpi)\textsuperscript{31}. This disruption to GC B-cell formation was originally proposed to be mediated by impaired T follicular helper-cell differentiation during Plasmodium infection\textsuperscript{26}. Here, we found that changes to the splenic B-cell phenotype is associated with inefficient CHIKV-neutralizing antibody generation, delayed virus resolution in the joints and elevated virus dissemination during chronic stages of CHIKV infection. These changes in viral load in the joints of co-infected mice did not aggravate joint pathology at the earliest time-point of viral resolution in co-infected mice (45 dpi). Nonetheless, such disruption to the B-cell humoral response during co-infection may negatively impact the recall response against secondary CHIKV infection.

Pathogenic virus-specific CD4\textsuperscript{+} T cells are the primary mediator of the peak of CHIKV-induced joint pathology\textsuperscript{30,35}. Induction of Th1 cytokines in both CHIKV-infected patients and mice suggests that CD4\textsuperscript{+} T cells mediate joint pathology through a Th1-mediated mechanism\textsuperscript{36,39–43}. In fact, co-infection suppresses peak joint pathology of CHIKV infection by limiting the infiltration of pathogenic virus-specific IFN\gamma (Th1)-producing CD4\textsuperscript{+} T cells in the joints. Here, suppression is mediated in two stages. Plasmodium infection induces apoptosis of a fraction of CD4\textsuperscript{+} T cells in the lymph node early after priming, and abrogates migration of the remaining live CD4\textsuperscript{+} T cells by suppressing chemotactic factors in the joints.

Prior to this study, the chemokines that regulate CD4\textsuperscript{+} T-cell migration during CHIKV infection were unknown. We show here that CXCR3, but not CCR5, is a critical mediator of CD4\textsuperscript{+} T-cell migration into infected joints. CXCR3 blockade in co-infected mice did not reduce joint swelling further, suggesting that the CXCR3-mediated pathway is already suppressed in co-infected mice. Suppression of joint swelling was more pronounced in co-infected mice with or without CXCR3 blockade as compared to CHIKV-infected mice with CXCR3 blockade. This finding suggests that suppression of CHIKV-induced joint swelling in co-infected mice is only partially dependent on CXCR3.

These findings of chikungunya protection during co-infection with Plasmodium have important implications when considering malaria intervention programmes. Effective malaria control programmes have declined the global incidence of malaria over the past decade\textsuperscript{10,44} and this is associated with the increasing trend of chikungunya incidence over a similar period of time\textsuperscript{8}. Interestingly, abrogation of systemic viral load during co-infection would lower vector competence, as lower blood viral titres would reduce the proportion of vectors being successfully infected\textsuperscript{45}. On the other hand, in the context of uncontrolled Plasmodium infection, the reduction of severe joint pathology by malaria co-infection would likely lower or mask CHIKV-related healthcare burden and prevalence. As the World Health Organisation scales up malaria intervention programmes to aggressively decline the incidence of malaria\textsuperscript{46}, the severity and numbers of CHIKV clinical cases, and vector competence, could indirectly increase. Therefore, alphavirus management should be integrated as part of the ongoing malaria intervention programme.
**Fig. 7** Co-infection abrogates CD4+ T-cell migration into the joints. **a** CD4+ T-cell in vivo migration assay. **b** In vivo migration assay showing number of recovered CHIKV-infected donor pLN CD4+ T cells (pooled) in the joints of CHIKV-infected or CHIKV+PbA-infected recipients (all groups n = 5). Representative dot plots displaying recovered donor-cell gating in 10,000 CD45+ cells in the footpad. **c** Joint inflammation of CHIKV (no transfer controls), CHIKV donor transferred to CHIKV recipient, CHIKV + PbA (no transfer controls) and CHIKV donor transferred to CHIKV + PbA recipient (all groups n ≥ 5). **d** Concentration of MIP-1α, MIP-1β, RANTES and CXCL10 in the joint-footpad cell lysate of mock (n = 5), CHIKV (n = 5) and CHIKV + PbA (n = 6) at 6 dpi. **e** Joint inflammation and **f** viraemia of CHIKV + Rat IgG (n = 6), CHIKV + CXCR3Ab (n = 6), CHIKV + PbA + Rat IgG (n = 6) and CHIKV + PbA + CXCR3Ab (all groups n ≥ 6). Joint vascular leakage was determined by Evan’s blue assay. All data were analyzed by Mann–Whitney two-tailed test (ns; not significant, *P < 0.05 and **P < 0.01). Each data point in the dot plot corresponds one mouse. Data represent the means ± SD. Abbreviations: CHIKV, Chikungunya virus; dpi, days post infection; ns, not significant; PbA, Plasmodium berghei-ANKA
Methods

NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06227-9 | www.nature.com/naturecommunications

Mice. Male and female WT, CCR5−/−, Lx1−/−, and IFNγ−/− mice (aged 5–7 weeks) were maintained on a C57BL/6J background. All experiments were age and gender matched. All mice were bred and housed under specific pathogen-free conditions in the Biological Resource Centre, Agency for Science, Technology and Research, Singapore. All experiments and procedures were approved by the Institutional Animal Care and Use Committee (IACUC: 140908) of the Agency for Science, Technology and Research, Singapore, in accordance with the guidelines of the Agri-Food and Veterinary Authority and the National Advisory Committee for Laboratory Animal Research of Singapore.

Pathogens and infection. The lethal P. berghei ANKA (PbA) clone 15C1y was used to induce experimental cerebral malaria (ECM)47. The P. yoelii yoelii 17XL clone 1.1 (Py17x) was used to induce non-lethal malaria48. Infected red blood cells (iRBC) were prepared by in vivo serial passage in C57BL/6J mice and blood samples were collected in liquid nitrogen in line with this publication. The CHIKV strain (SGP11) was previously isolated from blood samples taken from patients with CHIKV infection, admitted to the National University Hospital Singapore during the 2008 outbreak in Singapore49. The CHIKV variant expressing firefly luciferase (CHIKV-luc) or Zs-Green was constructed using a full-length interferin solution. CHIKV was propagated in Aedes albopictus C6/36 cultures (ATCC®CRL-1660™) and quantified by standard plaque assay in Vero E6 cells (ATCC® CCL-81™) as plaque forming units (PFU)50. Mice were infected with PbA by intraperitoneal (i.p.) injection of 106 iRBC and with CHIKV by subcutaneous inoculation of 106 PFU CHIKV (in 30 μL PBS) in the ventral side of the right hind footpad towards the ankle.

CHIKV disease monitoring in mice. Viraeemia was monitored daily from 1 day post-infection (dpi) until 8 dpi, and subsequently on every alternate day until 14 dpi. Briefly, 10 μL of blood collected from the tail vein was diluted in 120 μL PBS and 10 μL of citrate-phosphate-dextrose solution (Sigma-Aldrich). Viral RNA was extracted with QiAamp Viral RNA kit (Qagen) in accordance to manufacturer’s protocol. To measure the levels of replicating virus the extracted samples, RNA copies of negative sense nsP1 were quantified using quantitative RT-PCR. Primers and probe sequences were adapted from Plaskon et al.51 to target the same region of CHIKV nsP1. Brieﬂy, mice were anesthetised with ketamine-xylazine (150 mg/kg of ketamine; 10 mg/kg of xylazine), perfused intracardially with CHIKV by subcutaneous inoculation of 106 PFU CHIKV (in 30 μL PBS) in the ventral side of the right hind footpad towards the ankle.

Histology of joint footpad tissues. Mice were euthanised by perfusion with PBS post anesthesia and tissues were harvested and fixed in 10% neutral buffered formalin, and cut into 5 μm-thick sections for hematoxylin and eosin (H&E) staining52. Histopathological examination was carried out in a blinded fashion based on the presence of oedema, inflammation, muscle necrosis, tendinitis, and synovitis in mouse joint. Severity of grading was assigned on the following scale: 1–minimal; 2—mild; 3—moderate, 4—marked & 5—severe as previously described53. Stained sections were scanned using a Leica SCN400 slide scanner (Leica Microsystems GmbH, Germany) at a 20x magnification and exported to the SlidePath Digital Image system (Leica microsystem GmbH, Germany). CD3 expression was analyzed using cytoplasmic/membranous algorithms within the Leica SlidePath Tissue Image Analysis (tissue IA) software. The results among the different groups were computed and analyzed for statistical significance.

Quantification of joint vascular leakage by tracer assay. A Tracer 653 Assay (Molecular Targeting Technology, Inc) was performed as previously described36. Briefly, 100 μl tracer solution was injected (i.v) into each mouse, and the tracer solution that entered the joints was quantified using the IVIS. Regions of interest were drawn using Living Image 3.0 software, and average radiance [Log10(pfi/cm²/s)] was determined.

Leukocyte profiling in the joints, pLN and spleen. Joints, pLN and spleen were surgically excised and processed to obtain a homogenous cell suspension. For spleens, tissue was dissociated in RPMI medium containing 10% FBS (complete RPMI) and passed through a 70 μm cell strainer. For leukocyte profiling, tissue and spleen samples were homogenized using a rotor-stator homogenizer (Xiril Dispomix)52. Homogenized tissues were placed in clean Eppendorf tubes and mixed thoroughbly with 230 μL of chloroform, and allowed to stand for 2 min in room temp. Tissue mixtures were centrifuged at 12 000 g for 10 min at 4 °C. The aqueous phase was collected into a clean Eppendorf tube, and an equal volume of 70% ethanol was added in and mixed. Total RNA was subsequently extracted with RNeasy kit (Qiagen) following manufacturer’s protocol. RNA copies of negative sense nsP1 were subsequently quantified using quantitative RT-PCR.

Plasmodium disease monitoring in mice. Parasitaemia was monitored by flow cytometry daily from 3 dpi to 12 dpi and subsequently on alternate days33. Briefly, 1 μl of blood was collected in 100 μl of PBS and stained in 1 μl of Hoechst (800 μM; Sigma), 0.5 μl of dihydroethidium (1 μg/ml; Sigma), 0.5 μl of PBS and 2 μl of monomeric antibody CD45 coupled to Allophycocyanin (Molecular Biosciences; Cat no. 110-120-544). The blood preparation was incubated for 20 min before addition of 400 μl PBS. Stained samples were acquired on a LSR II flow cytometer (BD Biosciences) using BD FACSdiva software and analyzed using Flowjo software. Plasmodium infected RBCs were determined as Hoechst+ /dihydroethidium + /CD45− cells.

In vivo IFNγ neutralization and CXCR3 blockade. Anti-mouse IFNγ (0.5 mg; clone XMGL12; Bioxcell; Cat no. BE0555) was administered on −4, −2, 0 and 2 dpi via i.p injection. Anti-mouse CXCR3 (0.5 mg; clone CXCR3-173; Bioxcell; Cat no. BE0249) was administered on 0, 2, 4 and 6 dpi via i.p. injection. Control groups were given Rat IgG (Sigma Aldrich) at similar dosage and timing as treatment groups.

Splenectomy. Mice aged 4-weeks old were anesthetised with 80 μl ketamine: xylazine (150 mg/kg/10 mg/kg). Incisions were made on the left flank, and the primary artery connecting the spleen to the other organs located within the fat was seared. Post-surgery, enrofloxacin (5 mg/kg) and PBS (1 ml) was given and mice were monitored for recovery. A control, sham operation included similar incisions to the skin, without spleen removal and similar antibiotic treatment post-surgery. ~5 weeks were given for mice to completely recover from surgery prior to further experiments, hence infection in these mice were delayed to 9 weeks old.

Immunohistochemistry (IHC) and image analysis. Immunohistochemical staining of the joint-footpad was performed using a polyclonal α-mouse CD3 antibody (1:200 dilution; Dako; Cat no. A0452), as previously described52. Stained sections were scanned using a Leica SCN400 slide scanner (Leica Microsystems GmbH, Germany) at a 20x magnification and exported to the SlidePath Digital Image system (Leica microsystem GmbH, Germany). CD3 expression was analyzed using cytoplasmic/membranous algorithms within the Leica SlidePath Tissue Image Analysis (tissue IA) software. The results among the different groups were computed and analyzed for statistical significance.

Quantiﬁcation of joint vascular leakage by tracer assay. A Tracer 653 Assay (Molecular Targeting Technology, Inc) was performed as previously described36. Briefly, 100 μl tracer solution was injected (i.v) into each mouse, and the tracer solution that entered the joints was quantified using the IVIS. Regions of interest were drawn using Living Image 3.0 software, and average radiance [Log10(pfi/cm²/s)] was determined.
Quantification of apoptosis. Apoptosis of isolated pLN cells was determined by Annexin V assay (eBioscience; Cat no. 88-8005-72) according to the manufacturer’s protocol. Briefly, 10^6 pLN cells underwent surface staining of for 20 min followed by staining with fixable viability dye (1:500 dilution; FVD; eBioscience; Cat no. 65-0866-14) for 30 min on ice. Cells were then stained with FITC-conjugated Annexin V for 15 min followed by acquisition using a LSR II flow cytometer. Late apoptotic cells were defined as Annexin V+ FITC− and early apoptotic cells were Annexin V− FITC+. Representative gating strategy is shown in Supplementary Fig. 13.

Quantification of CHIKV-specific CD4+ T cells by ELISPOT. IFNγ ELISPOT assays (MBTech; Cat no. 3321-2 A) were conducted using isolated CD4+ T cells from 10^6 pLN or footpad cells were stimulated with 5 × 10^6 virions and 200,000 naive splenocytes following manufacturer’s protocol. Cells were stimulated with the virus in RPMI medium supplemented with 10% FBS and 30 U/mL IL2 (Sigma-Aldrich) for 18 h. The number of spots was quantified using an ImmunoSpot 5.0 Analyzer Professional DC (Cellular Technology Ltd), and the data were back calculated as the number of virus-specific CD4+ T cells per organ.

Quantification of CHIKV-specific IgM and Total IgG. A virion-based ELISA was used to quantify IgM and total IgG levels in the sera. CHIKV-coated (10^6 virions/well) in 50 mL PBS) polystyrene 96-well MaxiSorp plates (Nunc) were blocked with PBS containing 0.05% Tween 20 (PBST) and 5% nonfat milk for 1.5 h at 37°C. Sera from test groups were heat-inactivated and diluted in antibody diluent (0.05% PBST = 2.5% nonfat milk) at 1:2000 for IgM and total IgG quantification respectively. 100 μl of diluted sera per well was added and allowed to incubate for 1 h at 37°C. Subsequently, sera were washed off and 100 μl of secondary antibody, horseradish peroxidase-conjugated goat anti-mouse IgG (1:20,000 dilution; Santa Cruz; Cat no. SC-2064) were added and allowed to incubate for 30 min. ELISA assays were developed using Tetramethylbenzidine (TMB) substrate and terminated with Stop reagent (Sigma-Aldrich). Absorbance was measured at 450 nm. The neutralizing activity of sera was tested in a plaque reduction assay using a 36plex mouse ProcartaPlexTM luminex assay (Cat no. EPX360-26092-901) according to manufacturer’s protocol. Data are expressed as pg/mL in the footpad lystate.

Statistical analysis. Statistical analyses were performed according to the parametric or nonparametric distribution of the data using Prism 6 (GraphPad Software). Normality tests were performed by D’Agostino-Pearson omnibus normality test. All data with a normal distribution were analyzed by unpaired T-test or one-way ANOVA with Tukey’s post-hoc test. All data that did not meet the normality requirements were analyzed by Mann-Whitney 2-tailed analysis or Kruskal-Wallis with Dunn’s multiple comparisons. P values < 0.05 were considered statistically significant.

Data availability. The data that support the findings of this study are available from the corresponding author upon request.

Received: 22 March 2018 Accepted: 24 August 2018
Published online: 25 September 2018

References

1. Suhrbier, A., Jaffar-Bandjee, M. C., & Gasque, P. Arboviral alphaviruses— an overview. Nat. Rev. Rheumatol. 8, 420–429 (2012).
2. Lwande, O. W. et al. Global emergence of Alphaviruses that cause arthritis in humans. Infect. Ecol. Epidemiol. 5, 2983S (2015).
3. Powers, A. M., Brault, A. C., Tesh, R. B. & Weaver, S. C. Re-emergence of Chikungunya and O’nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J. Gen. Virol. 81, 471–479 (2000).
4. Storm, N. et al. Human cases of Sindbis fever in South Africa, 2006–2010. Epidemiol. Infect. 142, 234–238 (2014).
5. Harley, D., Sleigh, A. & Ritchie, S. Ross River virus transmission, infection, and disease: a cross-sectional review. Clin. Microbiol. Rev. 14, 909–932 (2001).
6. Naish, S., Hu, W., Mengersen, K. & Tong, S. Spatio-temporal patterns of Barmah Forest virus disease in Queensland, Australia. PLoS ONE 6, e25688 (2011).
7. Powers, A. M. et al. Genetic relationships among Mayaro and Una viruses suggest distinct patterns of transmission. Am. J. Trop. Med. Hyg. 75, 461–469 (2006).
8. Petersen, L. R. & Powers, A. M. Chikungunya: epidemiology. F1000 Res. 5, 1 (2016).
9. Powers, A. M. Chikungunya virus outbreak expansion and microevolutionary events affecting epidemiology and epidemic potential. Res. Rep. Trop. Med. 6, 11–19 (2015).
10. World Health Organization (WHO). World Malaria Report. (2016).
11. Hertz, J. T. et al. Chikungunya and dengue fever among hospitalized febrile patients in northern Thailand. Am. J. Trop. Med. Hyg. 86, 171–177 (2012).
12. Chipwaza, B. et al. Dengue and Chikungunya fever among viral diseases in outpatient febrile children in Kilsolo district hospital, Tanzania. PLoS Negl. Trop. Dis. 8, e3335 (2014).
13. Baba, M. et al. Evidence of arbovirus co-infection in suspected febrile malaria and typhoid patients in Nigeria. J. Infect. Dev. Cities. 7, 51–59 (2013).
14. Ayorinde, A. F., Oyeyi, A. M., Nosegbe, N. O. & Folarin, O. A. A survey of malaria and some arboviral infections among suspected febrile patients visiting a health centre in Simawa, Ogun State, Nigeria. J. Infect. Public Health 9, 52–59 (2016).
15. Waggoner, J. et al. Malaria and chikungunya detected using molecular diagnostics among Febrile Kenyan children. Open Forum Infect. Dis. 4, ofx110 (2017).
16. Tzeen, A. et al. Concurrent infection with Plasmodium vivax and the Dengue and Chikungunya viruses in a Paediatric Patient from New Delhi, India in 2016. Intervirology. (2017).
17. Sow, A. et al. Concurrent malaria and arbovirus infections in Redouguo, southeastern Senegal. Malar. J. 15, 47 (2016).
18. Dhalo, D. et al. Landscape ecology of sylvatic chikungunya virus and mosquito vectors in southeastern Senegal. PLoS Negl. Trop. Dis. 6, e1649 (2012).
23. De Souza, J. B., Williamson, K. H., Otani, T. & Playfair, J. H. Early gamma interferon interferon responses in lethal and nonlethal murine blood-stage malaria. *J. Infect. Immun.* 65, 1593–1598 (1997).

24. Carvalho, L. J., Ferreira-da-Cruz, M. F., Daniel-Ribeiro, C. T., Pelajo-Machado, M. & Lenzi, H. L. Germinal center architecture disturbance during Plasmodium berghei ANKA infection in CBA mice. *Malar. J.* 14, 128 (2015).

25. Alves, F. A. et al. Severe malaria infections impair germinal center responses by inhibiting T follicular helper cell differentiation. *Cell Rep.* 14, 68–81 (2016).

26. Taylor, J. J., Pape, K. A. & Jenkins, M. K. A germinal center-independent pathway generates unswitched memory B cells early in the primary response. *J. Pathol.* 231, 220–230 (2013).

27. Sanchez-Torres, L., Rodriguez-Ropon, A., Aguilar-Medina, M. & Favila-Y.H.C., S.N.A., J.J.L.T., C.Y.P.L., W.W.L.L., T.K.C., C.C. and R.R. conducted the material in this article are included in the material. If material is not included in the indicated otherwise in a credit line to the material. If material is not included in the

Acknowledgements
We thank Eleanor Pung and Zhisheng Her for assistance in the animal studies. We thank Anis Larbi and the SlgN Flow Cytometry core for assistance with cytometry analyses, Esther Mok from the SlgN Immune Monitoring Group for support in the luminescent assay and the SlgN Mouse Core for support in animal breeding. We thank Professor Andres Merits from the University of Tartu for providing the infectious clone of the tagged chikungunya virus used in this project. We also thank Insight Editing London for language editing the manuscript prior to submission. This research was funded by the Singapore Immunology Network (SlgN), Agency for Science, Technology and Research (A*STAR) core grant and supported by the Biomedical Research Council (A*STAR). Yi-Hao Chan and Cheryl Y.P. Lee are supported by the A*STAR Graduate Scholarship. The funders had no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.

Author contributions
T.H.T., L.F.P.N. and L.R. conceived and supervised the study. T.H.T., F.M.L., K.G., M.V.K. and K.H. designed the experiments. G.O.O.D., Y.H.C., S.N.A., J.J.L.T., C.Y.P.L., W.W.L.L., T.K.C., C.C. and R.R. conducted the experiments and performed data analysis. T.H.T., F.M.L., G.C., L.R. and L.F.P.N. wrote the manuscript.

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-06227-9.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.